-+ 0.00%
-+ 0.00%
-+ 0.00%

Pulmonx Highlights $12 Billion Global Opportunity for Zephyr Valves in Investor Presentation

PUBT·10/27/2026 20:31:47
Listen to the news
Pulmonx Highlights $12 Billion Global Opportunity for Zephyr Valves in Investor Presentation
  • Pulmonx reported third-quarter 2026 revenue of $22.8 million in an investor presentation, with US revenue of $14.9 million.
  • Gross margin was 76%; cash, cash equivalents and marketable securities totaled $52.7 million as of September 30, 2026.
  • The presentation estimated a $12 billion global opportunity for Zephyr valves across 1.2 million eligible patients.
  • Investigational AeriSeal technology could expand the addressable market by at least 20% by making currently ineligible patients eligible for Zephyr treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.